Wen Gao

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 6

Top Topics

Infectious Diseases

Mesenchymal Stem Cells

Prognostic Factors

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Wen Gao, Jianxiang Liu, Xiaolei Wang, Jingwen Li, Xuezhi Zhang, Hui Ye, Jiang Li, Xinhong Dong, Binbin Liu, Chi Wang, Ying Xu, Gui-Gen Teng, Yuling Tian, Jinpei Dong, Chaoyi Ge, Hong Cheng
Simplified Helicobacter pylori therapy for patients with penicillin allergy: a randomised controlled trial of vonoprazan-tetracycline dual therapy. Gut (2024)
Wen Gao, Jianxiang Liu, Xiaolei Wang, Jingwen Li, Xuezhi Zhang, Hui Ye, Jiang Li, Xinhong Dong, Binbin Liu, Chi Wang, Ying Xu, Gui-Gen Teng, Yuling Tian, Jinpei Dong, Chaoyi Ge, Hong Cheng
Simplified Helicobacter pylori therapy for patients with penicillin allergy: a randomised controlled trial of vonoprazan-tetracycline dual therapy. Gut 73 (9) (2024)
Wen Gao, Jianxiang Liu, Xiaolei Wang, Jingwen Li, Xuezhi Zhang, Hui Ye, Jiang Li, Xinhong Dong, Binbin Liu, Chi Wang, Ying Xu, Gui-Gen Teng, Yuling Tian, Jinpei Dong, Chaoyi Ge, Hong Cheng
Simplified Helicobacter pylori therapy for patients with penicillin allergy: a randomised controlled trial of vonoprazan-tetracycline dual therapy. Gut 73 (9) (2024)
Wen Gao, Jianxiang Liu, Xiaolei Wang, Jingwen Li, Xuezhi Zhang, Hui Ye, Jiang Li, Xinhong Dong, Binbin Liu, Chi Wang, Ying Xu, Gui-Gen Teng, Yuling Tian, Jinpei Dong, Chaoyi Ge, Hong Cheng
Simplified Helicobacter pylori therapy for patients with penicillin allergy: a randomised controlled trial of vonoprazan-tetracycline dual therapy. Gut 73 (9) (2024)
Si-Yu Li, Jiang Li, Xin-Hong Dong, Gui-Gen Teng, Wei Zhang, Hong Cheng, Wen Gao, Yun Dai, Xiao-He Zhang, Wei-Hong Wang
The effect of previous eradication failure on antibiotic resistance of Helicobacter pylori: A retrospective study over 8 years in Beijing. Helicobacter 26 (4) (2021)
Wen Gao, Hui Ye, Xin Deng, Chi Wang, Ying Xu, Yixuan Li, Xue-Zhi Zhang, Hong Cheng
Rabeprazole-amoxicillin dual therapy as first-line treatment for H pylori eradication in special patients: A retrospective, real-life study. Helicobacter 25 (5) (2020)